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with a vote of 265-142.

1lowever, the subsequent

revised version was seven votes short of overriding the

The State Children's Health Insurance Program President's veto.
(SCIHIP) is a national program which began in 1997.
The revised bill maintained the $35 billion expansion
SCI PIIprovides health insurance for those families who proposed in the first version, but also was amended
cannot afford private insurance, but whose incomes are to include concessions to some of the President's
not low enough to qualify them for Medicaid. SCI HP objections. Ihe added provisions include making
was created in an effort to quell the rising numbers of
illegal immigrants ineligible for coverage, and phasing
children lacking health coverage.
adults out of the program one year earlier than had been
SCIPll1 is a partnership between federal and state proposed in the original bill. Notably, the cigarette
governments. Each state runs its program pursuant tax, which Bush also opposed,, was reintroduced in the
to provisions issued by the Center for Medicare and revised bill in spite of the President's objection. Despite
Medicaid Services (CMS). SCIP gives states the the noted concessions in the bill, it is expected that
flexibility to design their programs separately from President Bush's veto will not be overturned.
Medicaid, use Funds from SCHIP to expand their
Medicaid program, or combine SCH1IP and Medicaid.
According to CMS, SCHIP covered 6.9 million children
in 2006.
Despite the successes of the SCHIP program, the
number of uninsured children continues to rise; several
states have not had sufficient funding to successfully
implement the program. The federal law authorizing
SCIHIP expired in September 2007. Until the bill is
reauthorized. no new federal SCHIP funds will be made
available for the upcoming and future fiscal years. This
fall, both the House and the Senate passed a bipartisan
measure to expand the program under H.R. 976. The
proposed bill, the Children's Health Insurance Program
Reauthorization Act of 2007, would expand coverage
to include more than 4 million additional participants
over the next five years. The bill also called for a $35
billion budget increase for five years, increasing SCH1
IIP
spending to $60 billion through 2010. Under the bill,
the expansion of the SCHIP program would be funded
by a nationwide tax increase of 61 cents per cigarette
pack.
On October 3, 2007, President Bush vetoed the
reauthorization of the legislation, claiming that
enactment of the bill would lead to health care
federalization and expand SCHlIP beyond its original
purpose. President Bush stated he would be open to a
compromise, but would not agree to endorse a proposal
that wxould expand the number of childien coxvered hx
SCHIP. On October 18, 2007. the House fell 13 votes
short (273-156) of the txwo-thirds inajorits required to
oxverride the President's v eto. On October 25, 2007,
the House passed a rexvised version of the svetoed bill,

OIGRettlease
k<
s Repo rt on FDA'sOerih of
ClIin iCa ITrFialIS
Before being introduced into the marketplace, federal
law requires that all new drugs and medical devices are
to be tested in clinical trials to ensure their safety and
effectiveness. IThe Food and rug Administration's
(FDA) oversight of clinical trials ensures that those
responsible for conducting or overseeing clinical trials
- sponsors of a new drug or medical device clinical
investigators, and institutional review boards (IRI)
- comply with regulations designed to advance the
public's health and protect the rights, safety, and wellbeing of study participants.
Prompted by a congressional inquiry regarding
weaknesses in the FDA's oversight of clinical trials and
a series ofnews articles expressing similar concerns, the
Office of the Inspector General (01), Department ot
Health and luman Services, carried out a two-pronged
review to (1) determine the extent to which the FDA
conducted inspections of clinical trials during fiscal
years (FY) 2000-2005, and (2) assess the EDA's process
for inspecting clinical trials.
In a report released September 2007, the OIG concluded
that the FDA's efforts to effectively oversee clinical
trials wxere bampered by a lack ot data and departmental
coordination. The agency did not knoxx hoxx many
clinical trials xvere on-going. oi hoxx many clinical
trial sites xxere involsved. The EDAxwxas also unable to
identify all IRBs. Using data extrapolated from otber
goxvemnent sources, the 01G estimnated that of the
likely 350.000 clinical trial sites associated xxith newv
drugs or medical dexvices, the F-DA inspected less tban

one percent of these sites between IFY 2000-2005. In addition, the OIG
found that most of the IFDA's inspections focused on completed trials rather
than the on-going trials where human subject protection was most critical.
There were also inconsistent classifications of the violations found at trial
sites and, in many cases, the most serious violations were downgraded to
less serious classifications. To further exacerbate the problem, the FDA's
guidance and regulations for clinical trials are outdated, and do not address
the complexities of large clinical trials involving multiple sites within and
outside of the United States.
The OIG identified several important steps that the FDA should take to
improve its oversight of clinical trials, including: (1) develop a clinical trial
database that includes all clinical trials; (2) create an Institutional Review
Board registry; (3) create a cross-center database that allows for complete
tracking of FDA inspections; (4) establish a mechanism to provide feedback
to investigators on their inspection reports and findings; and (5) seek legal
authority to provide oversight that reflects current clinical trial practices.
To read the complete OIG report visit: www.oig.hhsgov/oei/reports/oei01-06-00160.pd.

C('reatidn g a P riv at e C a us e o,,f A ctIon fr IHIe aIt h carePivac
The Health Insurance Portability and Accountability Act (HIPAA), more
commonly known as the HIPAAPrivacy Rule, has increased the prominence
of patient privacy as a health law issue. However, since HIPAA became
effective in 2003, the U.S. Department of Health and Hunan Services
(HHS) has not imposed any civil monetary penalties for HIRA violations.
HIPAA's enforcement authority is limited to action by the HHS Office of
Civil Rights, and no private or state-based litigation is sanctioned under
the current regulations. Ihis has led to concerns about the effectiveness of
IIIPAAs current enforcement approach -an approach that has focused on
voluntary compliance, corrective actions, and resolution agreements. In an
effort to improve IHIPAA'k s enforcement scheme., Senators Patrick Leahy
(D-VT) and Edward Kennedy (D-MA) introduced the Iealth Information
Privacy and Security Act of 2007 (IHIPSA), or Senate Bill 1814 a new
healthcare privacy bill designed to provide more stringent privacy standards
and safeguards in addition to harsher civil and criminal penalties for privacy
violations.
One of the notable provisions of IPSA would alter the existing privacy
framework by creating of a private right of enforcement for patients who
suffer healthcaie privacy iolations under IIPSAVlndei this proposal,
indixviduals could stand to receive compensatory damagers, attorney 's
fees, and punitisve damages for certain blatant violations. Perhaps as
significantly, HIPSA wxould extend the existing enforcement authority to
the State Attornes Gcneral's offices and any local agencies thes reeognize.
The State Attorney General's offices and othcr authorities oiv en pcrmission
to do so xwill specifically be permitted to file a civil action in fedcral district
court as a means of potcntially obtaining cisvil pcnalties from entities that
fail to adequately protet patients' prisvacy rights. HIPSA wxould oxverride
any inconsistent proxvisions of IHIPAA.
For the moment, the bill has stalled after being referred to the Committee
on Health. Education, Labor, and Pensions. HIPSA has received sparse
public attention and support so far, but this could easily change if one

of the presidential candidates takes a stance on this proposal. Ihe Bush
administration has not expressed any interest in this bill, which was
expected since bill implies the current administration's approach to IlPAA
enforcement is failing. Given its progressive construction, IIPSA's
eventual passage in any form may depend on which party succeeds in
winning the Presidency in 2008.

SmallBusiess

ealthcare Reform

T-he Senate Finance Committee has recently considered expanding health
care coverage for employees of small businesses. The recent Senate hearing
covered the following topics: making coverage more portable; creating
association health plans: reducing the cost of individual market coverage;

and creating health care tax credits.
Hlalf of the nation's 47 million uninsured citizens work for small businesses.
Continually increasing healthcare costs negatively and disproportionately
affect small businesses. One proposal to address this problem includes
arranging for small companies to coalesce with other small businesses for
the limited purpose of purchasing an insurance policy, thereby spreading
risks associated with health care costs across a larger pool of employees.
However, critics of this proposal note that member companies who have
healthier employees will not likely be amenable to a plan of this nature.
Presidential candidates from both parties have released proposals for
healthcare reform. Senator Hillars Clinton (D-NY) proposes a health
care plan which will require all Americans to obtain insurance. Her plan
will offer tax breaks to small companies and subsidies for low-income
individuals. Senator Barack Obaina (D-IL) proposes a national health
care plan similar to the insurance plan that federal employees are currently
entitled to receive. Former Senator John Edwards (D-NC) suggests a plan
that includes combining insurance pools, tax credits, and expanding the
Medicare Program.
Republican candidates tend to propose health care reforms that favor tax
credits over government subsidies. Former New York Mayor Rudy Giuliani
proposes expanding health savings accounts. Former Massachusetts
Governor Mitt Romney proposes deregulating the private insurance market
in an effort to drive down premiums. Senator John McCain (R-AZ)
proposes allowing insurers to cover individuals who move from state-tostate.
Regardless ofwhich plan may be implemented in the future, experts predict
that no changes will be made to current health care policy until after the
prcsidcntial election in Novemnber 2008.

